Chemotherapy-induced chemobrain and cognitive decline: A pharmacological perspective on neurovascular injury as a therapeutic target
Advances in Translational Research · 2026
DOI: 10.1556/1661.2026.00111 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Translational Research, 2026. Verfasst von Dorina Nagy und 11 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 168 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Chemotherapy-induced cognitive impairment, commonly referred to as chemobrain, represents a major and increasingly recognized long-term consequence of cancer treatment, contributing to persistent cognitive decline in a substantial proportion of cancer survivors. While traditionally attributed to direct neuronal toxicity, accumulating evidence suggests that many chemotherapeutic agents exert their central nervous system effects through indirect, pharmacologically mediated mechanisms. Notably, most widely used chemotherapies have limited penetration across the intact blood–brain barrier, prompting a re-evaluation of how systemic cytotoxic agents disrupt brain function. This mini-review advances a neurovascular framework for understanding chemotherapy-induced chemobrain, emphasizing injury to the cerebral microvasculature as a key pathogenic axis. We synthesize emerging preclinical and translational data indicating that chemotherapeutic agents target the cerebrovascular endothelium, leading to persistent alterations in blood–brain barrier integrity, microvascular density, cerebral blood flow regulation, and neurovascular coupling. These changes create a permissive environment for chronic neuroinflammation, metabolic stress, and impaired neuronal support, ultimately manifesting as cognitive decline. By framing chemobrain as a consequence of neurovascular dysfunction driven by pharmacological off-target effects, this review highlights novel opportunities for therapeutic intervention. Targeting vascular injury pathways, endothelial dysfunction, and maladaptive stress responses may offer promising strategies to prevent or mitigate cognitive decline in cancer survivors, shifting the focus from symptomatic management toward mechanism-based neuroprotection.
Zitieren
APA
Nagy, D., Chandragiri, S. S., Kordestan, K. V., Ekambaram, S., Nagykaldi, M., Patai, R., Gulej, R., Nagaraja, R. Y., Brunner, E., Kristof, R., Shanmugarama, S., & Csiszar, A. (2026). Chemotherapy-induced chemobrain and cognitive decline: A pharmacological perspective on neurovascular injury as a therapeutic target. Advances in Translational Research. https://doi.org/10.1556/1661.2026.00111
Vancouver
Nagy D, Chandragiri SS, Kordestan KV, Ekambaram S, Nagykaldi M, Patai R, et al. Chemotherapy-induced chemobrain and cognitive decline: A pharmacological perspective on neurovascular injury as a therapeutic target. Advances in Translational Research. 2026. doi:10.1556/1661.2026.00111
BibTeX
@article{Nagy2026,
author = {Nagy, Dorina and Chandragiri, Siva Sai and Kordestan, Kiana Vali and Ekambaram, Shoba and Nagykaldi, Mark and Patai, Roland and Gulej, Rafal and Nagaraja, Raghavendra Yelahanka and Brunner, Evelyn and Kristof, Rebeka and Shanmugarama, Santny and Csiszar, Anna},
title = {Chemotherapy-induced chemobrain and cognitive decline: A pharmacological perspective on neurovascular injury as a therapeutic target},
journal = {Advances in Translational Research},
year = {2026},
doi = {10.1556/1661.2026.00111}
}
EUVIMED